Daxor Corp (DXR)
8.89
+0.32
(+3.73%)
USD |
NASDAQ |
Mar 28, 16:00
8.89
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 42.73M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -11.28% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 32.18 |
Price to Book Value | 1.256 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.0222 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 69.45% |
Profile
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. |
URL | https://www.daxor.com |
Investor Relations URL | http://www.daxor.com/investors/ |
HQ State/Province | Tennessee |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Small Cap/Growth |
Next Earnings Release | Aug. 28, 2024 (est.) |
Last Earnings Release | Mar. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jan. 05, 2018 |
Ratings
Profile
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. |
URL | https://www.daxor.com |
Investor Relations URL | http://www.daxor.com/investors/ |
HQ State/Province | Tennessee |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Small Cap/Growth |
Next Earnings Release | Aug. 28, 2024 (est.) |
Last Earnings Release | Mar. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jan. 05, 2018 |